{"slug":"site-agnostic","tag":"site-agnostic","variants":["site-agnostic"],"description":"No description yet","count":3,"kinds":{"cancer":3},"related":[{"slug":"subtype-page","tag":"subtype-page","shared":2}],"records":[{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","tldr":"Cancer found already spread, where doctors cannot find where it started. Genomic profiling finds a drug target in about a third of cases and tumour-agnostic approvals apply directly; the rest still rely on general-purpose chemotherapy, which is what those tests are changing."},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","tldr":"Favourable subsets of cancer of unknown primary are the roughly one in five cases where the pattern of spread, the microscope appearance or blood markers point strongly to a particular cancer even though no primary can be found. They are treated as that cancer would be, for example breast cancer for a woman with cancer only in armpit nodes, and many are curable or controllable for years."},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","tldr":"Unfavourable cancer of unknown primary is the large majority of cases, where a metastatic adenocarcinoma or poorly differentiated carcinoma fits no recognised pattern and its origin cannot be found. Treatment has long been general-purpose platinum chemotherapy, but CUPISCO showed that matching drugs to the tumour's genetic faults after short chemotherapy holds the disease longer."}]}